The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The impact of tumor hypoxia on the clinical efficacy of anti-PD-1 mAb treatment in recurrent/metastatic HNSCC patients (R/M).
 
Dan Paul Zandberg
Research Funding - Aduro Biotech (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Macrogenics (Inst); Merck (Inst)
 
Maria A Velez
No Relationships to Disclose
 
Ashley V. Menk
No Relationships to Disclose
 
Angen Liu
No Relationships to Disclose
 
Heath Devin Skinner
No Relationships to Disclose
 
Umamaheswar Duvvuri
No Relationships to Disclose
 
James Ohr
No Relationships to Disclose
 
Simion I. Chiosea
No Relationships to Disclose
 
Marci Lee Nilsen
No Relationships to Disclose
 
David Anthony Clump
No Relationships to Disclose
 
Robert L. Ferris
Consulting or Advisory Role - Aduro Biotech; Amgen; AstraZeneca/MedImmune; Bain Capital Life Sciences; Bristol-Myers Squibb; EMD Serono; GlaxoSmithKline; Iovance Biotherapeutics; Lilly; Macrogenics; Merck; Nanobiotix; Numab; Oncorus; Ono Pharmaceutical; Pfizer; PPD; Regeneron; Tesaro; Torque; TTMS; TTMS
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Tesaro; TTMS; VentiRx
 
Greg Delgoffe
Stock and Other Ownership Interests - TTMS
Consulting or Advisory Role - Merck; Pieris Pharmaceuticals; TTMS; Western Oncolytics
Research Funding - Bluebird Bio; Pfizer; Pieris Pharmaceuticals; TCR2 Therapeutics; TTMS